CSIMarket
 
Monte Rosa Therapeutics Inc   (GLUE)
Other Ticker:  
 

Monte Rosa Therapeutics Inc

Officers & Directors






  News about Monte Rosa Therapeutics Inc Key Personnel

Monte Rosa Therapeutics Forges Ahead with Ambitious Milestones Despite Recent Stock Drops



Monte Rosa Therapeutics, a leading biotechnology company specializing in the development of novel small molecule therapies, recently provided a comprehensive corporate update, highlighting its key anticipated milestones for the year 2024. However, the company's shares experienced a decline of -2.21% over the past five trading days, signaling an underlying concern among investors. Furthermore, an accumulated net loss of $-133 million during the 12-month period ending in Q3 2023 has resulted in a significant negative return on investment (ROI) of -48.57%.
Despite these challenges, Monte Rosa Therapeutics remains committed to its mission of revolutionizing drug discovery and making significant adv...






GLUE Management Effectiveness GLUE Revenue per Employee GLUE Income per Employee


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com